A new molecular imaging agent can accurately identify a crucial biomarker found among many different types of cancer ...
PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit looks back on the progress made toward better understanding and ...
Researchers have used a chemical compound to light up treatment-resistant cancers on imaging scans, in a breakthrough that ...
Researchers have used a chemical compound to light up treatment-resistant cancers on imaging scans, in a breakthrough that could help medical professionals better target and treat cancer.
Discover the latest advancements in small cell lung cancer through Novotech CRO’s in-depth disease analysis. Gain valuable insights into novel therapies, ongoing clinical trials, and future ...
MyChesCo on MSN19h
Promising New Radiopharmaceutical Shows Breakthrough Potential in Cancer TreatmentWEST CHESTER, PA — Molecular Targeting Technologies, Inc. (MTTI) has unveiled significant preclinical results for its ...
Researchers have used a chemical compound to light up treatment-resistant cancers on imaging scans, in a breakthrough that could help medical ...
GlobalData on MSN20h
GSK’s lung cancer therapy gains EMA PRIME designationGlaxoSmithKline (GSK)’s B7-H3-targeted antibody-drug conjugate (ADC), GSK’227 has gained priority medicines (PRIME) ...
The paper, published today in Nature Communications, shows therapy-resistant non-small cell lung cancer tumours ’lit up like a Christmas tree’ on PET scans when the radiotracer was injected. Tim ...
A team of doctors and researchers at MSK identified a new, rare type of small cell lung cancer that primarily affects younger ...
Cibisatamab is a monoclonal antibody commercialized by Roche, with a leading Phase II program in Squamous Non-Small Cell Lung Cancer.
The study characterizes the lung cancer tumor microenvironment, linking cellular compositions to immunotherapy resistance and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback